Close Menu

NEW YORK (360Dx) – Siemens Healthineers' launched its Atellica Solution IVD analyzer system two years ago with the aim of taking market share from industry heavyweights like Roche Diagnostics and Abbott Laboratories.

According to the company, that effort has shown early signs of success with, for instance, CEO Bernd Montag noting during the firm's Q1 2019 earnings call that more than 35 percent of the Atellica Solution systems the company had sold at that point were "competitive wins," meaning that the purchasers were actively considering other firms' systems.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.